Ophthalmic Manifestations in Patients with Blood Malignancies

Ocular complications can occur in up to 90% of patients with blood malignancies. Such complications range from direct infiltration to local hemostatic imbalance and treatment-related toxicity. This narrative review is based on a systematic computerized search of the literature conducted until Januar...

Full description

Saved in:
Bibliographic Details
Published in:Hematology reports 2024-03, Vol.16 (2), p.193-203
Main Authors: Rossi, Costanza, Buizza, Alessandro, Alessio, Giuseppe, Borselli, Massimiliano, Taloni, Andrea, Carnevali, Adriano, Carnovale Scalzo, Giovanna, Lucisano, Andrea, Scorcia, Vincenzo, Giannaccare, Giuseppe
Format: Article
Language:English
Subjects:
antineoplastic therapy toxicity
B-cell lymphoma
Blood
Blood cancer
Blood diseases
Disease management
Eye diseases
Graft-versus-host reaction
hematological malignancies
Hematology
Hematopoietic stem cells
Immunotherapy
Iris
Ischemia
Leukemia
leukemic retinopathy
Lymphocytes B
Lymphoma
Malignancy
Nervous system
ocular complications
ocular graft versus host disease
Optic nerve
Quality of life
Retina
Retinopathy
Review
Stem cell transplantation
Tomography
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ocular complications can occur in up to 90% of patients with blood malignancies. Such complications range from direct infiltration to local hemostatic imbalance and treatment-related toxicity. This narrative review is based on a systematic computerized search of the literature conducted until January 2024 and examines the common ocular complications associated with blood cancers. Ocular complications from primary disease include mass effects from ocular adnexal lymphomas and intraocular lymphomas, with B-cell lymphomas accounting for 95% of primary ocular presentations. Secondary disease involvement from systemic hematological malignancies can lead to a wide range of ocular manifestations, such as leukemic retinopathy. Furthermore, toxicity from antineoplastic therapies and ocular graft versus host disease (oGVHD) after hematopoietic stem cell transplantation present additional risks to ocular health. In conclusion, ocular complications in blood cancer patients are an integral part of patient management, requiring regular ophthalmic evaluations and close collaboration between oncologists and ophthalmologists. Advances in therapy and an increased focus on early symptom recognition are essential for preserving vision and enhancing patient quality of life.
ISSN:2038-8322
2038-8330
2038-8330
DOI:10.3390/hematolrep16020020